Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
Kodiak Sciences (Nasdaq: KOD) said it enrolled the first patients in its global Phase 3 ALTO trial of KSI-501 for diabetic macular edema. The study compares KSI-501 5 mg versus aflibercept 2 mg, aiming to show superiority and testing dosing intervals up to six months. About 910 patients are planned, with primary visual acuity endpoints at weeks 48-52.
How this was made
The 30-second read
Why it matters
The enrollment start moves ALTO from planning into active conduct, with a primary endpoint based on mean visual acuity change at Weeks 48 and 52 and a key secondary endpoint on DRSS improvement.
Market read
Traders may re-rate the probability-weighted timeline for KSI-501’s DME registrational evidence as ALTO begins enrollment, while awaiting future efficacy and durability signals.
What to watch
Key near-term risk is whether enrollment and dosing execution meet expectations across ~910 patients and multiple arms, which can affect timelines for future readouts.
Background
KSI-501 is Kodiak’s investigational anti-IL-6, VEGF-trap bispecific built on the ABC platform; ALTO is the second Phase 3 program after DAYBREAK in wet AMD.
Ticker impact
Kodiak announced first patient enrollment in its global Phase 3 ALTO trial for KSI-501 in diabetic macular edema, comparing against aflibercept.
Near-term sentiment likely modestly positive, with attention shifting to enrollment pace and future interim/topline readouts.
The article is a fresh, company-specific clinical development milestone (first patients enrolled) but provides no efficacy/safety results or updated guidance, so impact is more about progression than fundamentals.
Market effects
Reinforces competitive intensity in retinal disease biologics, highlighting IL-6 plus VEGF bispecific differentiation versus anti-VEGF monotherapy.
Limited direct regional spillover; clinical trial progress is company-specific.
Global Phase 3 enrollment can affect broader investor sentiment toward retinal pipeline durability strategies.
Counterpoint
First-patient enrollment is an operational milestone, not a clinical outcome; investors may discount it until efficacy and durability data emerge.
Key entities
- companyKodiak Sciences Inc.
Sponsor of KSI-501 and developer of the ALTO Phase 3 trial in diabetic macular edema.
- drugKSI-501
Investigational bispecific therapy targeting IL-6 and VEGF pathways for DME.
- clinical_trialALTO Study (KSMP002-S1)
Global, multicenter, randomized, double-masked Phase 3 trial of KSI-501 5 mg vs aflibercept 2 mg in center-involved DME.
- comparatorAflibercept
Monospecific anti-VEGF active comparator used in ALTO.
